Chromocell Therapeutics Total Revenue

Chromocell Therapeutics (CHRO) currently reports a total revenue of $43M as of June 2026. In the prior-year period, the figure was $0. That is below the sector sector average of $1.4B. Use the charts on this page to explore Chromocell Therapeutics's total revenue history and peer comparisons.

Chromocell Therapeutics's total revenue changed from $0 to $43M (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Chromocell Therapeutics's total revenue of $43M is lower than the its sector sector average of $1.4B. That is roughly 96.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Chromocell Therapeutics reported $43M in total revenue as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $43M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $1.4B. From there, open related valuation or income-statement pages for Chromocell Therapeutics, and consider following CHRO for alerts when major investors trade the stock.